Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.57 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.57 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28050241 | 0.83 | RAB9A (0.68) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL28728369 | 0.81 | RAB9A (0.66) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL29502497 | 0.79 | LMNA (0.61) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL29647608 | 0.79 | CYP3A4 (0.61) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL19538202 | 0.79 | RAB9A (0.56) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL2016737 | 0.79 | LMNA (0.61) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL14380967 | 0.79 | CYP3A4 (0.61) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL1800355 | 0.79 | CYP3A4 (0.61) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL4424794 | 0.79 | RAB9A (0.65) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 | |
| SCHEMBL12472842 | 0.79 | BCHE (0.71) | BCHETRPC3TRPC4TRPC5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-104892582-B | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-109053523-A | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| CN-101365676-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC (US) | 2009-02-11 | — | — | CN | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-0888344-A1 | SPIROCYCLE INTEGRIN INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5760029-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1997033887-A1 | SPIROCYCLE INTEGRIN INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | BCHE 2995/4885TRPC3 3710/4885TRPC4 4320/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | BCHE 2972/4885TRPC3 4361/4885TRPC4 4680/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | BCHE 4150/4885TRPC3 2880/4885TRPC4 4188/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | BCHE 2995/4885TRPC3 3710/4885TRPC4 4320/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | BCHE 2995/4885TRPC3 3710/4885TRPC4 4320/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | BCHE 2995/4885TRPC3 3710/4885TRPC4 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.